PH12021551540A1 - Anti-il-36r antibodies for treatment of palmoplantar pustulosis - Google Patents

Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Info

Publication number
PH12021551540A1
PH12021551540A1 PH12021551540A PH12021551540A PH12021551540A1 PH 12021551540 A1 PH12021551540 A1 PH 12021551540A1 PH 12021551540 A PH12021551540 A PH 12021551540A PH 12021551540 A PH12021551540 A PH 12021551540A PH 12021551540 A1 PH12021551540 A1 PH 12021551540A1
Authority
PH
Philippines
Prior art keywords
antibodies
treatment
palmoplantar pustulosis
pustulosis
palmoplantar
Prior art date
Application number
PH12021551540A
Other languages
English (en)
Inventor
Christian Thoma
Patrick Baum
Janine Lamar
Steven John Padula
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PH12021551540A1 publication Critical patent/PH12021551540A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PH12021551540A 2018-12-27 2021-06-26 Anti-il-36r antibodies for treatment of palmoplantar pustulosis PH12021551540A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862785316P 2018-12-27 2018-12-27
US201962815431P 2019-03-08 2019-03-08
US201962891464P 2019-08-26 2019-08-26
PCT/EP2019/086521 WO2020136101A1 (en) 2018-12-27 2019-12-20 Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Publications (1)

Publication Number Publication Date
PH12021551540A1 true PH12021551540A1 (en) 2022-02-21

Family

ID=69190739

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021551540A PH12021551540A1 (en) 2018-12-27 2021-06-26 Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Country Status (14)

Country Link
US (3) US20200207862A1 (https=)
EP (1) EP3902604A1 (https=)
JP (1) JP2022515480A (https=)
KR (1) KR20210119407A (https=)
CN (1) CN113301955A (https=)
AU (1) AU2019416727A1 (https=)
BR (1) BR112021010789A2 (https=)
CA (1) CA3124996A1 (https=)
CL (1) CL2021001685A1 (https=)
IL (1) IL284259A (https=)
MX (1) MX2021007807A (https=)
PH (1) PH12021551540A1 (https=)
TW (1) TW202037604A (https=)
WO (1) WO2020136101A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
US20220119538A1 (en) * 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
BR112023017717A2 (pt) 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
EP4370550A1 (en) * 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
KR20250122528A (ko) * 2022-12-23 2025-08-13 아이코사백스, 인크. 메타뉴모바이러스 융합(f) 단백질에 대한 항체 및 그 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN107660155B (zh) 2015-04-24 2021-02-02 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
CA3093692A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Also Published As

Publication number Publication date
US20230131364A1 (en) 2023-04-27
TW202037604A (zh) 2020-10-16
MX2021007807A (es) 2021-08-11
JP2022515480A (ja) 2022-02-18
BR112021010789A2 (pt) 2021-08-31
WO2020136101A1 (en) 2020-07-02
EP3902604A1 (en) 2021-11-03
US20230115617A1 (en) 2023-04-13
CA3124996A1 (en) 2020-07-02
AU2019416727A1 (en) 2021-07-22
IL284259A (en) 2021-08-31
CN113301955A (zh) 2021-08-24
US20200207862A1 (en) 2020-07-02
CL2021001685A1 (es) 2022-02-18
KR20210119407A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
PH12021551540A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
PE20171138A1 (es) Modulacion inmunitaria
PH12020551444A1 (en) Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
GT201700246A (es) Métodos y kits para tratar la depresión
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
PH12018502593A1 (en) Combinations of linagliptin and metformin
EA202091639A3 (ru) Лечение панкреатита
BR112017004059A2 (pt) dispositivo de hemoperfusão utilizável
NZ716627A (en) Methods of treating behavioral symptoms of neurological and mental disorders
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2020003049A (es) Semaglutida en la terapia medica.
EP4509616A3 (en) Use of cd36 to identify cancer subjects for treatment
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
MY200803A (en) Mpo inhibitors for use in medicine